حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Biocon Limited
BIOCONBiocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Address: 20th KM Hosur Road, Bengaluru, India, 560100
Analytics
سعر الهدف في وول ستريت
27 962.48 INRنسبة السعر إلى الأرباح
26.7304العائد الربحي
0.15 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية BIOCON
تحليلات الأرباح BIOCON
نمو الأرباح على مدى 5 سنوات
200 %النمو المستمر
1 سنةمعدل الدفع 5 سنوات في المتوسط
18 %تاريخ الأرباح BIOCON
تقييم الأسهم BIOCON
المالية BIOCON
نتائج | 2019 | ديناميات |